Non-Hodgkin lymphoma can occur concurrently with chronic phase-chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second-generation tyrosine kinase inhibitors and rituximab-CHOP for patients newly diagnosed with CML and non-Hodgkin lymphoma is effective for both diseases. However, we found that this treatment combination may induce severe myelosuppression.
Keywords: Chronic myeloid leukemia; myelosuppression; non‐Hodgkin lymphoma; primary mediastinal large B‐cell lymphoma; tyrosine kinase inhibitor.